References

Guideline for the early Management of patients with acute ischemic stroke: a guideline from the American Heart Association/American Stroke Association

10.1161/str.0000000000000513 · 2026 · External reference

Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging

10.1056/nejmoa1713973 · 2018 · External reference

Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct

10.1056/nejmoa1706442 · 2018 · External reference

Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials

10.1016/s0140-6736(16)00163-x · 2016 · External reference

Current perspectives on potential role of albumin in neuroprotection

10.1515/rns.2011.028 · 2011 · External reference

Human albumin therapy of acute ischemic stroke: marked neuroprotective efficacy at moderate doses and with a broad therapeutic window

10.1161/01.str.32.2.553 · 2001 · External reference

Albumin therapy of transient focal cerebral ischemia: in vivo analysis of dynamic microvascular responses

10.1161/hs0402.105555 · 2002 · External reference

The ALIAS Pilot Trial: a dose-escalation and safety study of albumin therapy for acute ischemic stroke--I: physiological responses and safety results

10.1161/01.str.0000231388.72646.05 · 2006 · External reference

The ALIAS Pilot Trial: a dose-escalation and safety study of albumin therapy for acute ischemic stroke--II: neurologic outcome and efficacy analysis

10.1161/01.str.0000231389.34701.b5 · 2006 · External reference

The albumin in acute stroke (ALIAS) multicenter clinical trial: safety analysis of part 1 and rationale and design of part 2

10.1161/strokeaha.110.596072 · 2011 · External reference

The albumin in acute stroke part 1 trial: an exploratory efficacy analysis

10.1161/strokeaha.110.610980 · 2011 · External reference

High-dose albumin treatment for acute ischaemic stroke (ALIAS) Part 2: a randomised, double-blind, phase 3, placebo-controlled trial

10.1016/s1474-4422(13)70223-0 · 2013 · External reference

Albumin Administration in Acute Ischemic Stroke: safety analysis of the ALIAS part 2 multicenter trial

10.1371/journal.pone.0131390 · 2015 · External reference

ALIAS (albumin in acute ischemic stroke) trials: analysis of the combined data from parts 1 and 2

10.1161/strokeaha.116.012825 · 2016 · External reference

Efficacy and safety of albumin combined with endovascular therapy in the treatment of patients with acute ischemic stroke: a randomized clinical trial

10.1038/s41467-026-72270-6 · 2026 · External reference

SPIRIT 2025 statement: updated guideline for protocols of randomised trials

10.1136/bmj-2024-081477 · 2025 · External reference

Chinese guidelines for the diagnosis and treatment of acute ischemic stroke 2023

10.3760/cma.j.cn113694-20240410-00221 · 2024 · External reference

Chinese guideline for the secondary prevention of ischemic stroke and transient ischemic attack 2022

10.3760/cma.j.cn113694-20220714-00548 · 2022 · External reference

Adaptive increase in sample size when interim results are promising: a practical guide with examples

10.1002/sim.4102 · 2011 · External reference

Updated priorities for cerebroprotection trials

10.1161/strokeaha.125.052147 · 2026 · External reference

Edaravone dexborneol versus placebo on functional outcomes in patients with acute ischaemic stroke undergoing endovascular thrombectomy (TASTE-2): randomised controlled trial

10.1136/bmj-2025-086850 · 2026 · External reference

Efficacy and safety of butylphthalide in patients with acute ischemic stroke: a randomized clinical trial

10.1001/jamaneurol.2023.1871 · 2023 · External reference

Safety and efficacy of ApTOLL in patients with ischemic stroke undergoing endovascular treatment: a phase 1/2 randomized clinical trial

10.1001/jamaneurol.2023.1660 · 2023 · External reference

Intra-arterial human serum albumin therapy following mechanical thrombectomy for acute ischemic stroke: the AMASS pilot trial

10.1136/jnis-2025-023998 · 2025 · External reference